.4 semaglutide 1.75mg increase feelings of fullness GLP-1s | AgelessRx

Insurance coverage remains inconsistent for both medications, particularly for the obesity indications

The GIP receptor activation provides additional metabolic benefits through pathways that pure GLP-1 agonists like semaglutide simply cannot access

Having moderate to severe diabetic retinopathy before starting the medication A history of poorly controlled blood sugar over many years High blood pressure that is not well managed Kidney disease or other diabetes-related complications Very rapid reduction in hemoglobin A1C levels within the first few months Rare cases of sudden, painless vision loss from optic nerve injury have been reported in people using GLP-1 receptor agonists

Ongoing Support Continue indefinitely or pause anytime

ALSO READ: Falsified Ozempic products flood the market, Sahpra urges caution Data from the World Obesitys Global Obesity Observatory shows South Africa has a growing overweight and obese population